Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of Aspirin/Clopidogrel Restart After EMR/ESD
NCT01621451Phase 4Unknown
- Sponsor
- Asan Medical Center
- Start
- Jun 2012
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin and clopidogrel in cardiovascular disease (CVD) and cerebrovascular disease (2 arms), sponsored by Asan Medical Center. Primary endpoint: Delayed Ulcer Bleeding Rate at 4 weeks. Status: unknown.
02
Drugs
aspirinclopidogrel
03
Conditions
cardiovascular disease (CVD)cerebrovascular disease
Beyond the preview
Go deeper on NCT01621451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621451.